Keywords: UK, NICE, Novartis, Nilotinib, Tasigna, Cost effectiveness, myeloid leukemia
Novartis disappointed by UK’s NICE preliminary recommendation on nilotinib
Article | 10 February 2010
Novartis Oncology, a UK unit of the Swiss drug major, says it disagrees with the National Institute for Health and Clinical Excellence’s (NICE) preliminary view that neither its Tasigna (nilotinib) nor dasatinib (Bristol-Myers Squibb’s Sprycel) should be recommended for use in the treatment of Philadelphia-chromosome positive (Ph+) chronic myeloid leukemia (CML) patients who are intolerant to imatinib (The Pharma Letter February 9).
T Enjoying this article? To continue reading you need to login, take a FREE trial or subscribe.
FREE unlimited, no obligation access to The Pharma Letter website for 30 days, normally worth £60!
Sign up in less than 60 seconds...no payment needed
Want to read the full article?
Take a 30 day FREE Trial worth £60
Take a no obligations 30 day trial.
Only one trial per user. Find out more details
Subscribe now
for unlimited access to all articles
Subscriptions are £60 per month, pay as you go.
Find out more details.
Already a subscriber? Click here to log in
- Ono Pharma buys Japanese rights to two cancer drugs in $340 million deal with Onyx
- GlaxoSmithKline sells Croatian research center to Galapagos, names new CFO and enters supply deal with Lonza; EMEA update on Avandia and Pandemrix
- Wyeth/Pfizer accused of using ghostwritten articles to overstate benefits of HRT
- China’s liver cancer drug market forecast to nearly triple to $144 million in 2014
- International sales rep quality survey views BRIC markets
